Cargando…
Is Salivary S100B a Biomarker of Traumatic Brain Injury? A Pilot Study
Traumatic brain injury (TBI) results in short and long-term disability neurodegeneration. Mild traumatic brain injury (mTBI) represents up to 85% of head injuries; diagnosis and early management is based on computed tomography (CT) or in-hospital observation, which are time- and cost- intensive. CT...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303321/ https://www.ncbi.nlm.nih.gov/pubmed/32595592 http://dx.doi.org/10.3389/fneur.2020.00528 |
_version_ | 1783548029296443392 |
---|---|
author | Janigro, Damir Kawata, Keisuke Silverman, Erika Marchi, Nicola Diaz-Arrastia, Ramon |
author_facet | Janigro, Damir Kawata, Keisuke Silverman, Erika Marchi, Nicola Diaz-Arrastia, Ramon |
author_sort | Janigro, Damir |
collection | PubMed |
description | Traumatic brain injury (TBI) results in short and long-term disability neurodegeneration. Mild traumatic brain injury (mTBI) represents up to 85% of head injuries; diagnosis and early management is based on computed tomography (CT) or in-hospital observation, which are time- and cost- intensive. CT involves exposure to potentially harmful ionizing radiation and >90% of the scans are negative. Blood-brain barrier (BBB) damage is suspected pathological event post-TBI contributing to long-term sequelae and a reliable and rapid point-of-care test to screen those who can safely forego acute head CT would be of great help in evaluating patients with an acute mTBI. In this pilot study, 15 adult patients with suspected TBI (mean age = 47 years, range 18–79) and 15 control subjects (mean age = 33 years, range 23–53) were enrolled. We found that the average salivary S100B level was 3.9 fold higher than blood S100B, regardless of the presence of pathology. [S100B](saliva) positively correlated with [S100B](serum) (Pearson' coefficient = 0.79; p < 0.01). Salivary S100B levels were as effective in differentiating TBI patients from control subjects as serum levels (Control vs. TBI: p < 0.01; Serum ROC(AUC) = 0.94 and Saliva ROC(AUC) = 0.75). I These initial results suggest that measuring salivary S100B could represent an alternative to serum S100B in the diagnosis of TBI. Larger and confirmatory trials are needed to define salivary biomarker kinetics in relation to TBI severity and the possible roles of gender, ethnicity and age in influencing salivary S100B levels. |
format | Online Article Text |
id | pubmed-7303321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73033212020-06-26 Is Salivary S100B a Biomarker of Traumatic Brain Injury? A Pilot Study Janigro, Damir Kawata, Keisuke Silverman, Erika Marchi, Nicola Diaz-Arrastia, Ramon Front Neurol Neurology Traumatic brain injury (TBI) results in short and long-term disability neurodegeneration. Mild traumatic brain injury (mTBI) represents up to 85% of head injuries; diagnosis and early management is based on computed tomography (CT) or in-hospital observation, which are time- and cost- intensive. CT involves exposure to potentially harmful ionizing radiation and >90% of the scans are negative. Blood-brain barrier (BBB) damage is suspected pathological event post-TBI contributing to long-term sequelae and a reliable and rapid point-of-care test to screen those who can safely forego acute head CT would be of great help in evaluating patients with an acute mTBI. In this pilot study, 15 adult patients with suspected TBI (mean age = 47 years, range 18–79) and 15 control subjects (mean age = 33 years, range 23–53) were enrolled. We found that the average salivary S100B level was 3.9 fold higher than blood S100B, regardless of the presence of pathology. [S100B](saliva) positively correlated with [S100B](serum) (Pearson' coefficient = 0.79; p < 0.01). Salivary S100B levels were as effective in differentiating TBI patients from control subjects as serum levels (Control vs. TBI: p < 0.01; Serum ROC(AUC) = 0.94 and Saliva ROC(AUC) = 0.75). I These initial results suggest that measuring salivary S100B could represent an alternative to serum S100B in the diagnosis of TBI. Larger and confirmatory trials are needed to define salivary biomarker kinetics in relation to TBI severity and the possible roles of gender, ethnicity and age in influencing salivary S100B levels. Frontiers Media S.A. 2020-06-12 /pmc/articles/PMC7303321/ /pubmed/32595592 http://dx.doi.org/10.3389/fneur.2020.00528 Text en Copyright © 2020 Janigro, Kawata, Silverman, Marchi and Diaz-Arrastia. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Janigro, Damir Kawata, Keisuke Silverman, Erika Marchi, Nicola Diaz-Arrastia, Ramon Is Salivary S100B a Biomarker of Traumatic Brain Injury? A Pilot Study |
title | Is Salivary S100B a Biomarker of Traumatic Brain Injury? A Pilot Study |
title_full | Is Salivary S100B a Biomarker of Traumatic Brain Injury? A Pilot Study |
title_fullStr | Is Salivary S100B a Biomarker of Traumatic Brain Injury? A Pilot Study |
title_full_unstemmed | Is Salivary S100B a Biomarker of Traumatic Brain Injury? A Pilot Study |
title_short | Is Salivary S100B a Biomarker of Traumatic Brain Injury? A Pilot Study |
title_sort | is salivary s100b a biomarker of traumatic brain injury? a pilot study |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303321/ https://www.ncbi.nlm.nih.gov/pubmed/32595592 http://dx.doi.org/10.3389/fneur.2020.00528 |
work_keys_str_mv | AT janigrodamir issalivarys100babiomarkeroftraumaticbraininjuryapilotstudy AT kawatakeisuke issalivarys100babiomarkeroftraumaticbraininjuryapilotstudy AT silvermanerika issalivarys100babiomarkeroftraumaticbraininjuryapilotstudy AT marchinicola issalivarys100babiomarkeroftraumaticbraininjuryapilotstudy AT diazarrastiaramon issalivarys100babiomarkeroftraumaticbraininjuryapilotstudy |